The apheresis market reached USD 3.32 billion in 2026 and is forecast to expand to USD 4.83 billion by 2031, reflecting a compound annual growth rate of 7.8 percent. Rising incidence of autoimmune and neurological disorders, coupled with technological advances in blood component separation, anchors this trajectory. The market encompasses multiple clinical modalities, with plasmapheresis commanding the largest share due to its application across autoimmune diseases, hematologic and renal disorders requiring plasma exchange.
What is driving growth
Autoimmune disorders affecting approximately 8 percent of the U.S. population in 2025 create sustained demand for therapeutic intervention spanning multiple decades of patient life. Neurological conditions requiring plasma exchange extend the addressable patient population further. Centrifugation-based apheresis systems, which dominate current installations, deliver superior efficiency in separating blood components and removing disease-causing antibodies, autoantibodies, and inflammatory cytokines. Equipment innovations that reduce procedure duration and improve clinical outcomes simultaneously expand clinician adoption and patient accessibility. Government support for blood donation infrastructure and transfusion service networks reinforces collection capacity and extends market reach.
Restraints and challenges
Apheresis device manufacturing and disposable production entail complex protocols, mandatory maintenance systems, and extended regulatory approval timelines that collectively drive production costs substantially higher than comparable medical devices. Developing economies provide inadequate reimbursement coverage, deterring patient uptake in price-sensitive regions. Raw material cost fluctuations and logistical disruptions compress margins particularly acutely for smaller regional manufacturers. Simultaneously, tightening environmental and safety compliance requirements across major markets extend product development cycles and increase certification expenses, favoring larger competitors with established regulatory expertise.
Centrifugation technology dominates the procedural landscape, prized for separation efficiency and component purity. By type, donor apheresis is projected to exhibit the highest growth rate over the forecast period, fueled by escalating global demand for plasma and blood derivatives alongside expanding voluntary donation infrastructure. Therapeutically, pediatric populations and leukemia patients represent emerging high-growth segments as clinical adoption expands beyond traditional adult applications.
Geographically, Asia Pacific leads overall market expansion, supported by industrial acceleration and favorable demographic profiles, while North America and Europe maintain substantial mature demand. Key competitors include Fresenius SE Co. KGaA, Haemonetics Corporation, Infomed SA, Therakos LLC, and Haier Biomedical, competing across device platforms and disposable product lines.
Companies profiled
- Fresenius SE
- Co. KGaA
- Haemonetics Corporation
- Infomed SA
- Therakos LLC
- Haier Biomedical
- Product Type Devices
- Disposables
For complete market sizing, forecasts, and competitive intelligence, read the full Apheresis Market — covering growth drivers, regional analysis, and leading company profiles through 2033.